OPTIMIZE Study Results Highlight Efficacy and Safety of XPHOZAH in Reducing Phosphate Levels in Patients with End-Stage Renal Disease.
Post-hoc analysis of the OPTIMIZE study supports Xphozah (tenapanor) as a potential treatment option for patients with uncontrolled type 2 diabetes and chronic kidney disease. The study found that tenapanor reduced albuminuria and improved glycemic control in patients with type 2 diabetes and chronic kidney disease.